Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 3/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | DPP4 | P27487 | 3/20 | 0.40 |
| ▸ | HRH1 | P35367 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | IDO1 | P14902 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.33 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6319190 | 0.78 | HRH1 (0.52) | PNMTTAAR1DPP4HRH1KDM4E | |
| SCHEMBL3142208 | 0.77 | IDO1 (0.43) | TAAR1HRH1IDO1ALDH1A1GAA | |
| SCHEMBL1581411 | 0.77 | ALDH1A1 (0.33) | TAAR1HRH1IDO1ALDH1A1GAA | |
| SCHEMBL410908 | 0.77 | L3MBTL1 (0.52) | TAAR1KDM4EIDO1HPGDMAPT | |
| SCHEMBL457980 | 0.77 | APOBEC3G (0.41) | TAAR1KDM4EIDO1HPGDALDH1A1 | |
| SCHEMBL30200411 | 0.76 | PNMT (0.46) | PNMTTAAR1DPP4HRH1KDM4E | |
| SCHEMBL18683266 | 0.76 | PNMT (0.46) | PNMTTAAR1DPP4HRH1KDM4E | |
| Water SCHEMBL5381049 | 0.76 | APOBEC3G (0.40) | TAAR1KDM4EIDO1HPGDALDH1A1 | |
| SCHEMBL9938733 | 0.75 | IDO1 (0.40) | TAAR1IDO1LOXL2 | |
| SCHEMBL9938061 | 0.75 | MPO (0.40) | IDO1LOXL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2015081280-A1 | BROMODOMAIN LIGANDS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION | COFERON, INC. (US) | 2015-06-04 | — | — | WO | disclosed |
| EP-2651917-A1 | DIMERIC IAP INHIBITORS | Novartis AG (CH) | 2013-10-23 | — | — | EP | disclosed |
| US-20130266590-A1 | DIMERIC IAP INHIBITORS | NOVARTIS AG (CH) | 2013-10-10 | — | — | US | disclosed |
| WO-2012080260-A1 | DIMERIC IAP INHIBITORS | NOVARTIS AG (CH) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130266590-A1 | DIMERIC IAP INHIBITORS | XIAP, BIRC5, BIRC2 | PNMT 3668/4885TAAR1 4440/4885DPP4 1034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.